Regulus Therapeutics Inc Quick Ratio (RGLS) starting from the first quarter 2025 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Regulus Therapeutics Inc   (NASDAQ: RGLS)

Regulus Therapeutics Inc 's Quick Ratio

RGLS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Regulus Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Regulus Therapeutics Inc 's Quick Ratio to 14.87, above Regulus Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Quick Ratio than Regulus Therapeutics Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 143, from total ranking in the fourth quarter 2024 at 194.

Explain Quick Ratio?
How much Cash & cash equivalents RGLS´s has?
What are RGLS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RGLS Quick Ratio (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1
Y / Y Current Liabilities Change -22.62 % -11.86 % -21.41 % -36.04 % -35.59 %
Y / Y Cash & cash equivalent Change -32.99 % 218.39 % 183.64 % 153.5 % 221.88 %
Quick Ratio MRQ 14.87 10.1 13.47 17.95 17.17
RGLS's Total Ranking # 143 # 194 # 229 # 73 # 164
Seq. Current Liabilities Change -41.37 % 15.69 % 23.16 % -7.37 % -33.22 %
Seq. Cash & cash equivalent Change -13.74 % -13.21 % -7.57 % -3.17 % 309.89 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 50
Healthcare Sector # 69
Overall Market # 143


Quick Ratio Statistics
High Average Low
17.95 6.18 0.42
(Jun 30 2024)   (Mar 31 2019)




Financial Statements
Regulus Therapeutics Inc 's Current Liabilities $ 4 Millions Visit RGLS's Balance sheet
Regulus Therapeutics Inc 's Cash & cash equivalent $ 65 Millions Visit RGLS's Balance sheet
Source of RGLS's Sales Visit RGLS's Sales by Geography


Cumulative Regulus Therapeutics Inc 's Quick Ratio

RGLS's Quick Ratio for the trailling 12 Months

RGLS Quick Ratio

 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -22.91 % -26.27 % -39.32 % -38.46 % -28.04 %
Y / Y Cash & cash equivalent TTM Growth 70.49 % 190.7 % 120.43 % 62.18 % 16.68 %
Quick Ratio TTM 13.66 14.25 11.69 8.9 6.18
Total Ranking TTM # 2714 # 1956 # 50 # 2356 # 2164
Seq. Current Liabilities TTM Growth -5.16 % -3.89 % -6.38 % -9.67 % -9.29 %
Seq. Cash & cash equivalent TTM Growth -9.06 % 17.15 % 22.92 % 30.2 % 55.05 %

Quick ratio ranking by company, industry and sector >> Back to RGLS Financial Strength Comparisons >> Go to Compare RGLS Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in RGLS's Current Liabilities to $4.40 millions, cumulative Quick Ratio to 13.66 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 419 other companies have achieved higher Quick Ratio than Regulus Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 1956 to 2714.

Explain Quick Ratio?
How much Cash & cash equivalents RGLS´s has?
What are RGLS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 420
Healthcare Sector # 836
Within the Market # 2714


trailing twelve months Quick Ratio Statistics
High Average Low
14.25 5.37 0.63
(Dec 31 2024)   (Sep 30 2019)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Bright Minds Biosciences Inc   35.59 $ 63.669  Millions$ 1.789  Millions
Roivant Sciences Ltd   32.71 $ 4,886.891  Millions$ 149.411  Millions
Septerna Inc   31.59 $ 336.005  Millions$ 10.638  Millions
Jade Biosciences Inc   31.53 $ 76.210  Millions$ 2.417  Millions
Terns Pharmaceuticals Inc   30.57 $ 334.264  Millions$ 10.935  Millions
Rapport Therapeutics Inc   30.41 $ 285.382  Millions$ 9.383  Millions
Arca Biopharma Inc  29.78 $ 349.094  Millions$ 11.723  Millions
Xbiotech Inc   28.82 $ 155.897  Millions$ 5.410  Millions
Tvardi Therapeutics Inc   28.54 $ 34.217  Millions$ 1.199  Millions
Vera Therapeutics Inc   28.49 $ 589.834  Millions$ 20.703  Millions
Fulcrum Therapeutics Inc   27.98 $ 226.603  Millions$ 8.100  Millions
Design Therapeutics Inc   27.89 $ 229.674  Millions$ 8.236  Millions
Monopar Therapeutics Inc   26.62 $ 39.711  Millions$ 1.492  Millions
Immunome Inc   26.18 $ 317.323  Millions$ 12.119  Millions
Agios Pharmaceuticals Inc   25.40 $ 893.375  Millions$ 35.170  Millions
Aardvark Therapeutics Inc   25.31 $ 151.260  Millions$ 5.976  Millions
Anebulo Pharmaceuticals Inc   24.32 $ 13.280  Millions$ 0.546  Millions
Bicara Therapeutics Inc   24.17 $ 462.065  Millions$ 19.120  Millions
Mbx Biosciences Inc   22.97 $ 240.786  Millions$ 10.481  Millions
Structure Therapeutics Inc   22.94 $ 836.882  Millions$ 36.487  Millions
Tyra Biosciences Inc   22.39 $ 318.943  Millions$ 14.246  Millions
Avalo Therapeutics Inc   22.28 $ 125.108  Millions$ 5.615  Millions
Crinetics Pharmaceuticals Inc   22.23 $ 1,274.124  Millions$ 57.311  Millions
Alto Neuroscience Inc   22.15 $ 160.754  Millions$ 7.257  Millions
Newamsterdam Pharma Company N v   22.13 $ 808.477  Millions$ 36.541  Millions
Boundless Bio Inc   21.81 $ 138.253  Millions$ 6.338  Millions
Contineum Therapeutics Inc   21.31 $ 190.710  Millions$ 8.949  Millions
Ideaya Biosciences Inc   21.28 $ 1,075.646  Millions$ 50.538  Millions
Neurogene Inc   20.76 $ 292.602  Millions$ 14.094  Millions

Date modified: 2026-09-26T07:09:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.